Do Peptides Need Refrigeration? What Stability Studies Report

What the published literature actually addresses

The question "do peptides need refrigeration" is asked about several different situations: an unopened lyophilised vial, a vial that has been reconstituted, a diluted solution in use, and a peptide sitting in a biological sample such as plasma. The published stability literature treats these as separate problems, because the measured outcomes differ. Rather than a single rule, researchers reported condition-specific results in which temperature, elapsed time, solvent, container and surrounding matrix each changed the amount of intact peptide recovered.

Stability studies typically report a measured concentration or a functional property at defined time points under defined storage conditions, and describe the point at which the measured value falls outside a pre-set acceptance range. That framing matters: a study showing loss after several hours at room temperature in whole blood says nothing directly about a sealed dry powder, and a study of a monoclonal antibody in a diluted infusion bag describes a different physical system again.

Dry powder versus solution: why the literature separates them

Regulatory labelling for approved lyophilised biological products conventionally distinguishes storage of the unreconstituted vial from an "in-use" period after reconstitution or dilution, and stability programmes generate separate data sets for each. The in-use question has been studied directly for large biologics: a combined physicochemical and functional assessment of pertuzumab reported that diluted preparations retained measured integrity across an extended in-use storage period under the conditions tested (PMID 36978206). That study examined a specific molecule, diluent and container system, and its authors framed the conclusion around those conditions rather than around biologics in general.

For smaller peptides in solution, solvent composition itself was a measured variable. A computational and experimental evaluation of a GLP-1-like peptide in ethanol–water mixtures reported that the solvent environment influenced the peptide's conformational behaviour and stability profile (PMID 35890357). The study combined simulation with laboratory measurement, illustrating that "in solution" is not one condition but many, depending on what the solution contains.

Temperature and time in biological matrices: what studies measured

Some of the most detailed peptide stability data come from laboratory medicine, where researchers measured how quickly analytes degrade in collected samples. A study of adrenocorticotropic hormone in whole blood examined the effect of storage conditions and reported that measured ACTH concentrations depended on how and for how long the blood was held before processing (PMID 39171091). A broader stability study of 81 analytes in human whole blood, serum and plasma reported analyte-specific behaviour, with stability varying by matrix and by storage interval rather than following one pattern across all measured substances (PMID 22285385).

Matrix choice alone changed results in some work. Researchers comparing pro-gastrin-releasing peptide in serum versus plasma reported differing stability between the two matrices under the storage conditions examined (PMID 18781094). Similarly, a study of glucagon-like peptide 1 and glucagon in human plasma reported that measured concentrations depended on sample handling and the additives present during collection and storage (PMID 25596009). These are enzymatic and matrix effects specific to blood samples; they are frequently cited in discussions of peptide fragility, but they describe peptides surrounded by active proteases, not peptides in a sealed pharmaceutical vial.

Room-temperature excursions and manufacturer-supplied data

The question of what happens when a refrigerated product is left out has been examined systematically using information supplied by manufacturers. A 20-year review of allowable room temperature excursions for refrigerated medications compiled manufacturer-provided excursion information for refrigerated products and reported that permitted excursion allowances differed substantially from product to product (PMID 35451022). The review's framing is important for the underlying question: excursion tolerance in that dataset was a product-level attribute determined by each manufacturer's own stability testing, not a property that could be generalised across an entire drug class (PMID 35451022).

That is the central limitation behind most online discussion of peptide storage. Where a specific approved product exists, the excursion information belongs to that product's stability file; where no such file exists, as with research-use-only materials, no equivalent published excursion data set has been established.

Formulation strategies that reduced cold-chain dependence

A separate research strand asks whether peptides and proteins can be formulated so that refrigeration matters less. Researchers describing thermal stabilisation of diverse biologics using reversible hydrogels reported that encapsulation protected multiple biologic cargoes against thermal stress in their experimental system (PMID 35930644). Work on navy-bean bioactive peptides reported that nanoliposomal encapsulation was accompanied by morphological, structural and biological changes in the peptide preparation, with the carrier acting as a protective environment (PMID 38647940).

Surface and excipient interactions were examined in other systems. A study of exfoliation and intercalation of montmorillonite by small peptides reported that short peptides interacted strongly with mineral surfaces and altered the layered structure of the clay (PMID 25825549), a reminder that peptides are not inert toward the materials around them. In vaccine development, researchers screening adjuvant systems for a peptide-based SARS-CoV-2 candidate reported that antigen and adjuvant combination was a central formulation variable in their evaluation (PMID 35456690). Longer-term storage of a complex biological preparation was also documented: a study of a platelet-rich plasma-based topical serum reported measured stability across an extended storage period under the conditions the authors tested (PMID 32654407).

What the evidence does and does not cover

What is notably absent from this list is a published study measuring the shelf life of unlabelled lyophilised research peptides held in a cupboard versus a refrigerator. Discussions in online forums frequently assert fixed durations for powder held at ambient temperature, but those figures do not trace to peer-reviewed measurements of the specific materials being discussed. The compiled excursion review found that even for licensed refrigerated medicines with full stability files, tolerances were assigned product by product (PMID 35451022).

Degradation and handling losses: What Studies Report

The measurable consequence described across this literature is loss of the intended molecule or of a measured function, not a toxicological event. Researchers reported that ACTH measurements shifted according to whole-blood storage conditions (PMID 39171091), that GLP-1 and glucagon concentrations in plasma depended on handling and additives (PMID 25596009), and that stability differed across 81 analytes depending on matrix and interval (PMID 22285385). Conversely, integrity was retained across the tested in-use period in the pertuzumab assessment (PMID 36978206) and across extended storage in the platelet-rich plasma serum study (PMID 32654407). None of these papers characterised the clinical effects of administering degraded material; that question sits outside the scope of the verified literature summarised here.

How to read stability claims critically

• Check the physical state. Data generated in plasma or whole blood, such as the 81-analyte survey (PMID 22285385), describe enzymatic environments that differ from a dry or buffered preparation.
• Check the molecule. The excursion review reported product-specific allowances rather than class-wide rules (PMID 35451022).
• Check the endpoint. Some studies measured concentration; the pertuzumab work paired physicochemical measures with functional assays (PMID 36978206).
• Check the formulation. Carriers and solvents changed outcomes in hydrogel (PMID 35930644), liposome (PMID 38647940) and ethanol–water (PMID 35890357) studies.

Bottom line from the literature

Across the studies summarised above, refrigeration functioned as one variable among several — alongside time, matrix, solvent, additives and formulation — that determined how much intact peptide or protein remained at a given time point. The only systematic dataset on leaving refrigerated medicines at room temperature was assembled from manufacturer-supplied information and reported wide product-to-product variation (PMID 35451022), which is why generalisations about "peptides" as a category are not supported by the papers cited here. This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified pharmacist for guidance about any specific product, its labelling or its handling requirements.

References

• Allowable room temperature excursions for refrigerated medications: A 20-year review (American Journal of Health-System Pharmacy, 2022)
• Stability of adrenocorticotropic hormone in whole blood samples: effects of storage conditions (Biochemia Medica, 2024)
• Stability study of 81 analytes in human whole blood, in serum and in plasma (Clinical Biochemistry, 2012)
• Thermal stabilization of diverse biologics using reversible hydrogels (Science Advances, 2022)
• Long-term stability of a novel platelet-rich plasma-based topical serum for cutaneous applications (Journal of Cosmetic Dermatology, 2021)
• Exfoliation and intercalation of montmorillonite by small peptides (Applied Clay Science, 2015)
• Computational and Experimental Evaluation of the Stability of a GLP-1-like Peptide in Ethanol-Water Mixtures (Pharmaceutics, 2022)
• Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems (Pharmaceutics, 2022)
• Protection of navy-bean bioactive peptides within nanoliposomes: morphological, structural and biological changes (Bioresources and Bioprocessing, 2023)
• Stability of glucagon-like peptide 1 and glucagon in human plasma (Endocrine Connections, 2015)
• Combined physicochemical and functional assessment of pertuzumab integrity supports extended in-use stability (Archiv der Pharmazie, 2023)
• Stability of pro-gastrin-releasing peptide in serum versus plasma (Tumour Biology, 2008)